摘要
分析研究CDH13甲基化和EZH2的表达在老年卵巢癌发病机制中的调控作用。选取2009年8月至2015年8月期间收治的160例老年卵巢癌患者进行研究,采用甲基化特异性聚合酶链式反应分析患者肿瘤组织与癌旁组织CDH13甲基化程度,采用ELISA法检测EZH2基因的表达水平。最终显示,卵巢癌组织中的CDH13基因甲基化率明显高于对照组和癌旁组织,IGF-1、IGF-2、EZH2、PTEN和COX-2蛋白的表达也明显高于对照组和癌旁组织,且差异显著,具有统计学意义(p<0.05);CDH13基因的甲基化及EZH2蛋白表达与卵巢癌的临床分期和预后密切相关,且随着患者临床分期的升高、年龄及肿瘤组织的增大、肿瘤分化程度的升高,CDH13基因的DNA甲基化率明显升高(p<0.05)。CDH13基因甲基化和EZH2基因表达与老年卵巢癌的临床分期和预后密切相关,可作为临床诊断及治疗的标志物。
The use of this study was to study the regulation of CDH13 methylation and EZH2 on the pathogenesis of ovarian cancer in elderly patients. 160 cases of elderly patients with ovarian cancer from August 2009 to August2015 were studied. The methylation of CDH13 was assayed by PCR while the EZH2 expression was detected by ELISA. The results showed the CDH13 methylation rate was higher in ovarian cancer elderly patients（p〈0.05）. The results also revealed that the expression of IGF-1, IGF-2, PETN and COX-2 were higher in ovarian cancer elderly patients, and the difference is statistically significant（p〈0.05）. In conclusion, CDH13 methylation and EZH2 were related with the clinical stage and prognosis of ovarian patients. When there was a rise in clinical stage, tumor differentiation, as well as an increase in age and tumor tissue, CDH13 methylation ratio significantly elevated（p〈0.05）, indicating it might be taken as indicators for clinical diagnosis and treatment effect.
出处
《基因组学与应用生物学》
CAS
CSCD
北大核心
2017年第12期4971-4977,共7页
Genomics and Applied Biology
基金
武汉市卫计委公共卫生科研项目(WG13D85)资助
